Table 1.
Study characteristics of included studies.
| Citation (First author et al., year) | No. of studies in meta-analysis | Location | no. of participants in meta-analysis | Mean age (year) | dose(g) | Health condition/ duration(wk) | Quality assessment scale and outcome |
|---|---|---|---|---|---|---|---|
| Casariego et al. 2013 | 4 | Spain | 284 | NR | 2.2 | T2DM 25 week | Yes (Jadad) 4/4 high |
| Abbasnezhad et al. 2020 | 6 | Iran | 468 | 53 | 1.9 | Liver disorders 20 week | Yes (Cochrane) 6/6 high |
| Abolfathi et al. 2020 | 4 | Malaysia | 254 | 53 | 0.84 | NAFLD 15 week | Yes (Jadad) 4/4 high |
| Asadi et al. 2020 | 23 | Iran | 1,533 | NR | 1.8 | Metabolic disorders 16 week | Yes (Cochrane) 18/23 high |
| Asbaghi et al. 2020 | 8 | Iran | 508 | 53 | 2.4 | T2DM 19 week | Yes (Cochrane) 8/8 high |
| Askarpour et al. 2019 | 56 | Iran | 3,004 | 50 | 1.6 | Metabolic disorders 18 week | Yes (Cochrane) NR |
| Chen et al. 2014 | 21 | China | 637 | 52.5 | 0.73 | ESRD 15 week | Yes (Cochrane) 6/21 high |
| Choi et al. 2020 | 6 | Korea | 375 | 53 | 1.6 | Metabolic syndrome 14 week | Yes (Cochrane) 4/6 high |
| Huang et al. 2013 | 12 | China | 391 | 49 | 0.54 | ESRD 18 week | Yes (Jadad) 8/12 high |
| Liao et al. 2021 | 3 | China | 496 | 26 | 2.08 | PCOS 12 week | Yes (Cochrane) 3/3 high |
| Yang et al. 2014 | 11 | China | 397 | 50 | 1.18 | ESRD 20 week | Yes (Cochrane) 1/11 high |
| Gholipur et al.2018 | 10 | Iran | 466 | NR | 1 | CKD 21 week | Yes (Cochrane) 5/10 high |
| Fathizadeh et al. 2019 | NR | Iran | NR | NR | NR | NR | NR |